INIS
levels
100%
patients
100%
sensitivity
100%
trajectories
100%
reduction
50%
sex
50%
concentration
50%
modeling
50%
injuries
50%
diseases
25%
cardiovascular diseases
25%
drugs
25%
females
25%
risks
25%
comparative evaluations
25%
biological markers
25%
interactions
25%
insulin
25%
Medicine and Dentistry
Randomized Controlled Trial
100%
Maturity Onset Diabetes of the Young
100%
Glycon
100%
Cardiac Troponin
100%
Troponin T
100%
Post-Hoc Analysis
100%
Troponin I
100%
Placebo
50%
Cardiovascular System
20%
Heart Muscle Injury
20%
Biological Marker
10%
Clinical Study
10%
Diabetes
10%
Patient with Type 2 Diabetes
10%
Cardiovascular Disease
10%
Patient with Diabetes
10%
Insulin Treatment
10%
Macrovascular Disease
10%
Keyphrases
Randomized Controlled Trial
100%
Cardiac Troponin
100%
High-sensitivity Cardiac Troponin
100%
Type 2 Diabetic Patients
100%
Metformin
100%
Placebo
36%
Type 2 Diabetes Mellitus (T2DM)
18%
Troponin Levels
18%
Troponin
18%
T Level
18%
Advanced Type
18%
Subclinical Myocardial Injury
18%
Clinically Significant
9%
Trial Registration
9%
Treatment Group
9%
Diabetes
9%
Cardiovascular Outcomes
9%
Mean Group
9%
Disease Risk
9%
Insulin Therapy
9%
Smoking Status
9%
History of Cardiovascular Disease
9%
Female Sex
9%
Cardioprotection
9%
Treatment Interaction
9%
Prognostic Marker
9%
Patients with Diabetes
9%
Smoking History
9%
Linear Mixed-effects Regression Model
9%
Regression Modeling
9%
Macrovascular Disease
9%
Cardiovascular Endpoints
9%
Onset Type
9%
Placebo Groups
9%
Linear Mixed Effects Modeling
9%
Newly Onset
9%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Non Insulin Dependent Diabetes Mellitus
100%
Metformin
100%
Troponin T
100%
Troponin I
100%
Placebo
62%
Troponin
37%
Heart Muscle Injury
25%
Disease
12%
Clinical Study
12%
Biological Marker
12%
Cardiovascular Disease
12%
Biochemistry, Genetics and Molecular Biology
Randomized Controlled Trial
100%
Troponin T
100%
Troponin I
100%
Cardiac Troponin
100%
Clinical Study
10%